Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations-Reference-Cited by-同舟云学术

Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations

Published:2021-01-11 Issue:1 Volume:9 Page:225-238
ISSN:2366-1070
Container-title:Oncology and Therapy
language:en
Short-container-title:Oncol Ther

Author:

Kolberg Hans-Christian,Demetriou Georgia Savva,Hanes Vladimir

Funder

Amgen

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://link.springer.com/content/pdf/10.1007/s40487-020-00129-x.pdf

Reference23 articles.

1. KANJINTI™ (trastuzumab-anns) for injection, for intravenous use. Prescribing information. Amgen Inc., Thousand Oaks, CA: June 2019. https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/kanjinti/kanjinti_pi.ashx. Accessed 4 Nov 2019.

2. KANJINTI. Summary of product characteristics. Amgen Europe B.V., the Netherlands: September 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/kanjinti#productinformation-section. Accessed 4 Nov 2019.

3. Generics and Biosimilars Initiative (GaBi) Online. Biosimilars approved in Japan: 14 December, 2018. http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Japan. Accessed 5 May 2020.

4. Thill M, Thatcher N, Hanes V, Lyman GH. Biosimilars: what the oncologist should know. Future Oncol. 2019;15(10):1147–65.

5. Curigliano G, O’Connor DP, Rosenberg JA, Jacobs I. Biosimilars: extrapolation for oncology. Crit Rev Oncol Hematol. 2016;104:131–7.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biosimilars in Gastric Cancer;Biosimilars for Cancer Treatment;2024

2. Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer;Biomedicines;2022-08-21

3. Biosimilar Monoclonal Antibodies in Latin America;Biosimilars [Working Title];2021-12-07